Yarrow Bioscience, Inc

YARW

Healthcare Biotechnology

Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024.

Revenue
+40.6%
EPS
+46.0%
Free cash flow
+81.6%

Quarter to June 2026, against a year earlier

15.60 2.00 +14.71%
Market cap
$147.2M
P/E
n/m
Fwd P/E
n/m
Dividend yield
0.10%
F-score
3/9
ROIC
0.00%
Net debt / EBITDA
1.0×
Dividend safety
20/100
Dec '25 Dec '24 Dec '23 Dec '22 Jan '22 Dec '21 Jan '21 Dec '20 Jan '20 Dec '19
Piotroski F-Score
3 2 4 3 — 4 — 3 — 1
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(31.09) (10.78) (8.20) (24.14) — (12.74) — (14.10) — (7.07)
P/S ratio
43.54 284.78 168.21 16.52 62.48 56.40 10.00 9.75 33.48 36.12
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(70.34) (31.45) (8.74) (50.58) — (27.84) — (32.51) — (16.32)
P/Operating CF
(6.59) (15.85) (13.88) (1.64) (5.81) (5.24) (8.27) (8.07) (4.66) (5.03)
Beneish M-Score
— — — — — 6.27 — 35.23 — —
P/B ratio
0.89 2.74 0.80 0.25 1.20 1.08 5.60 5.46 5.90 6.37
Dividend Safety Score
20 — — — — — — — — —
EV/Sales
109.57 295.03 105.34 91.31 17.66 81.95 8.79 8.54 20.59 23.23
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
(1.87) (4.33) (1.75) (1.49) (0.29) (1.35) (1.34) (1.31) (0.86) (0.97)
Current Ratio
12.53 4.35 12.73 4.10 4.10 3.43 3.43 4.01 4.07 2.61
Net Debt/EBITDA
0.95 1.34 3.16 0.91 0.91 1.10 1.10 0.13 0.27 0.43
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.88 0.91 1.86
ROE
(66.33%) (56.57%) (47.44%) (58.14%) 0.00% (170.28%) 0.00% (928.19%) 0.00% (128.66%)
ROA
(54.57%) (48.40%) (41.10%) (43.06%) 0.00% (91.21%) 0.00% (292.24%) 0.00% (86.10%)
ROIC
0.00% 0.00% 0.00% (9,442.46%) 0.00% (420.68%) 0.00% (1,406.53%) 0.00% 0.00%
Return on Tangible Assets
(95.59%) (80.10%) (32.18%) (80.23%) (124.88%) (162.48%) (162.48%) (386.94%) (376.15%) (190.46%)
Average Days of Receivables
0.00 0.00 0.00 0.00 3,958.38 2,972.93 2,972.93 275.04 275.04 111.23
Earnings Yield
(105.61%) (28.06%) (308.68%) (301.81%) (127.33%) (141.07%) (150.96%) (154.79%) (41.49%) (38.46%)
Free Cash Flow Yield
(134.24%) (23.94%) (35.69%) (372.01%) (97.09%) (107.57%) (65.35%) (67.01%) (71.75%) (66.49%)
Free Cash Flow per Share
(38.72) (40.02) (123.31) (458.40) (9.17) (985.44) (19.72) (3,810.97) (76.11) (7,916.17)
Book value per Share
32.46 61.15 431.80 489.83 9.86 850.28 17.01 1,041.47 20.82 1,869.68
Free Cash Flow
(33.12) (34.09) (25.34) (29.20) (29.20) (56.37) (56.37) (137.19) (137.08) (74.41)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026